DiaMedica Therapeutics
Stock Forecast, Prediction & Price Target
DiaMedica Therapeutics Financial Estimates
DiaMedica Therapeutics Revenue Estimates
DiaMedica Therapeutics EBITDA Estimates
DiaMedica Therapeutics Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | |
Revenue
% change YoY
| $0 N/A | $0 0% | $0 0% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $54M Low: $54M High: $54M avg. 0% | Avg: $220M Low: $220M High: $220M avg. 307.40% | |
Net Income
% change YoY
| $-13.59M N/A | $-13.67M -0.61% | $-19.38M -41.71% | Avg: $-34.58M Low: $-30.93M High: $-22.47M avg. -78.45% | Avg: $-40.03M Low: $-22.79M High: $-22.79M avg. -15.76% | Avg: $0 Low: $0 High: $0 avg. 100% | |
EBITDA
% change YoY
| $-13.62M N/A | $-13.97M -2.59% | $-19.30M -38.15% | Avg: $0 Low: $0 High: $0 avg. 100% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $0 Low: $0 High: $0 avg. 0% | |
EPS
% change YoY
| -$0.65 N/A | -$0.52 20% | -$0.6 -15.38% | Avg: -$0.82 Low: -$0.95 High: -$0.69 avg. -36.66% | Avg: -$0.7 Low: -$0.7 High: -$0.7 avg. 14.63% | Avg: $0 Low: $0 High: $0 avg. 100% | |
Operating Expenses
% change YoY
| $13.64M N/A | $14.00M 2.60% | $21.26M 51.89% | Avg: $0 Low: $0 High: $0 avg. -100% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $0 Low: $0 High: $0 avg. 0% | |
FAQ
What is DiaMedica Therapeutics stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of -31.40% in 2025-2027.
We have gathered data from 2 analysts. Their low estimate is -30.93M, average is -34.58M and high is -22.47M.
What is DiaMedica Therapeutics stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 102.46% in 2025-2027.
We have gathered data from 2 analysts. Their low revenue estimate is N/A, average is N/A and high is N/A.
What is DiaMedica Therapeutics stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of -7.34% in 2025-2027.
We have gathered data from 2 analysts. Their low earnings per share estimate is -$0.95, average is -$0.82 and high is $-0.69.
What is the best performing analyst?
In the last twelve months analysts have been covering DiaMedica Therapeutics stock. The most successful analyst is Alex Nowak.